SCHEMBL21166545

SCHEMBL21166545

CCCC(C)c1cc(OC)cc(OC)c1Cl

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAS1R3 Q7RTX0 1/20 0.35
TAS1R1 Q7RTX1 1/20 0.35
CYP2D6 P10635 2/20 0.35
ADRA2A P08913 2/20 0.34
ADRA1A P35348 2/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
PAK1 Q13153 1/20 0.34
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
LMNA P02545 1/20 0.33
GLA P06280 1/20 0.33
GAA P10253 1/20 0.33
MAPT P10636 1/20 0.33
HPGD P15428 1/20 0.33
HSD17B10 Q99714 1/20 0.33
ADRB2 P07550 1/20 0.33
ADRB1 P08588 1/20 0.33
ADRB3 P13945 1/20 0.33
THRB P10828 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21166499 0.87 CYP2D6 (0.37) CYP2D6ADRA2AADRA1AMEN1KMT2A
SCHEMBL16133969 0.79 CYP2D6 (0.41) CYP2D6ADRA2AADRA1AMEN1KMT2A
SCHEMBL18897414 0.79 MEN1 (0.36) MEN1KMT2APAK1KDM4EMAPT
SCHEMBL21423114 0.77 CA12 (0.47) CYP2D6ADRA2AADRA1AALDH1A1ADRB2
SCHEMBL19389253 0.77 CYP2D6 (0.56) CYP2D6ADRA2AADRA1AMEN1KMT2A
SCHEMBL18948439 0.75 HTR2A (0.40) TAS1R3TAS1R1CYP2D6ADRA2AADRA1A
SCHEMBL24282607 0.75 MEN1 (0.39) TAS1R3TAS1R1MEN1KMT2AKDM4E
SCHEMBL17522202 0.73 CALM1 (0.40) ADRA2AADRA1AMEN1KMT2AKDM4E
SCHEMBL19801119 0.73 TAAR1 (0.34) THRBRORC
SCHEMBL19420216 0.72 L3MBTL1 (0.46) TAS1R3TAS1R1MEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190218220-A1 HETEROARYL COMPOUNDS AND USES THEREOF BRISTOL-MYERS SQUIBB COMPANY 2019-07-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190218220-A1 HETEROARYL COMPOUNDS AND USES THEREOF PRKACA, PRKDC, AURKC TAS1R3 4797/4885TAS1R1 4831/4885CYP2D6 3307/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.